Vital Therapies, Inc. — Q2 2015 Form 10-Q
Filing identity: The supplied filing is for Vital Therapies, Inc., not IMMUNIC, INC. It covers the quarter and six months ended June 30, 2015; the financial statements are unaudited.
Business context and reporting period
Vital Therapies was a clinical-stage biotherapeutics company developing ELAD, an extracorporeal cell-based therapy for liver failure. ELAD was in Phase 3 development, and the company had no revenue from planned principal operations. The company reported one operating segment.
Financial performance and liquidity
| Metric | Q2 2015 | Q2 2014 | Six months 2015 | Six months 2014 |
|---|---|---|---|---|
| Revenue | No product revenue | No product revenue | No significant product revenue | No significant product revenue |
| Research and development expense | $11.5 million | $9.1 million | $23.3 million | $18.3 million |
| General and administrative expense | $3.5 million | $2.5 million | $6.6 million | $5.2 million |
| Total operating expenses | $15.1 million | $11.6 million | $29.9 million | $23.5 million |
| Net loss | $15.1 million | $10.2 million | $29.9 million | $20.9 million |
| Operating cash used | Not separately stated | Not separately stated | $28.6 million | $19.2 million |
Gross margin and operating margin are not meaningful because the company had no product revenue. Cash and cash equivalents were $71.9 million at June 30, 2015, down from $102.2 million at December 31, 2014. Restricted cash was $1.4 million. Current assets totaled $75.4 million and current liabilities $10.0 million. The filing reports no borrowings or debt balance. Accumulated deficit was $180.7 million.
Investing activities used $1.8 million in the first half, primarily for equipment and facility improvements. Financing activities provided $0.1 million, mainly from stock-option exercises, compared with $73.2 million in the first half of 2014, which included IPO and preferred-stock proceeds.
Material changes versus the comparable period
- Q2 operating expenses rose 30% year over year; first-half expenses rose 27%. R&D increases reflected clinical-trial support, mechanism-of-action research, BLA preparation, staffing, and facility overhead.
- First-half operating cash use increased to $28.6 million from $19.2 million, while the prior-year period included substantial financing proceeds.
- Q2 2014 included $1.5 million of other income from termination of future purchase-right liabilities upon the IPO-related conversion of preferred stock. First-half 2014 included $2.6 million of this income, plus preferred-stock deemed-dividend amortization and accretion affecting common-stockholder loss per share.
- Property and equipment, net, increased to $4.2 million from $3.1 million at year-end 2014, including increased construction in progress.
Outlook, clinical development, risks, and unusual items
- Management expected existing cash to fund operations into the third quarter of 2016 under its current plan, excluding significant commercial infrastructure spending. It expected additional funding would be needed to complete enrollment in VTI-210 and VTI-212; successful VTI-208 results followed by BLA and launch preparation could increase cash burn and financing needs.
- VTI-208, a Phase 3 trial in alcohol-induced liver decompensation, completed enrollment of 203 subjects in January 2015. Management said current cash was expected to fund development through topline results, but the filing does not provide a clear date for those results.
- As of July 29, 2015, VTI-210, a Phase 3 trial in severe acute alcoholic hepatitis, had enrolled 18 subjects and had 38 sites open. VTI-212, a Phase 2 program in fulminant hepatic and surgery-induced liver failure, had enrolled seven subjects; Phase 2 data were anticipated in 2016.
- Management anticipated higher R&D spending in 2015 as trials, research, and regulatory work continued. The company had no approved products and expected continuing losses; product revenue was not expected before 2017 at the earliest.
- Key risks include whether trials show statistically significant benefit, FDA concerns about open-label design and inconsistent standards of care, possible need for additional confirmatory trials, regulatory and manufacturing requirements, patient safety, enrollment, reliance on single-source suppliers, and ability to raise capital. The company’s China marketing application remained under review, with timing uncertain.
- The effective shelf registration permitted up to $200 million of company securities, including an at-the-market facility of up to $75 million within that amount, and resale of up to 2.5 million shares by certain holders. No securities under the shelf had been sold as of June 30, 2015.
- Management disclosed material weaknesses in internal control over financial reporting, including inadequate segregation of duties and ineffective review. Remediation and testing were underway, but disclosure controls and procedures were concluded to be ineffective as of June 30, 2015.
- The company reported no current litigation it believed would materially affect it. It also reported no material change in its market-risk assessment.
Important facts for investors to verify
- Confirm the filing is for Vital Therapies, Inc.; the request identifies IMMUNIC, INC.
- Check subsequent VTI-208 topline results and whether they supported a BLA, as well as the trial’s design limitations and regulatory feedback.
- Track VTI-210 and VTI-212 enrollment, timelines, costs, and whether additional trials or funding became necessary.
- Assess the assumptions behind the projected cash runway and the company’s financing options, including potential dilution from shelf or at-the-market offerings.
- Review progress in remediating the disclosed internal-control material weaknesses and any later changes in control effectiveness.